Pharmaceutical Technology, 2017 Solid Dosage Supplement (PDF)

Pharmaceutical Technology, 2017 Solid Dosage Supplement (PDF)

April 1, 2017

Publication

Article

Pharmaceutical TechnologyPharmaceutical Technology-04-01-2017

Volume 2017 Supplement

Issue 2

Click the title above to open the Pharmaceutical Technology 2017 Solid Dosage Supplement in an interactive PDF format.

External Link - PharmTech_NA_SolidDose_Supp2017.pdf

Download Issue PDF

Articles in this issue

Preventing Contamination During Sterile Powder Transfer

Using Spectroscopic and Virtual Sensor PAT in Continuous Solid-Dosage Manufacturing

Continuous Manufacturing: Separating Hype from Reality

Making PAT and Continuous Manufacturing Accessible

Improving the Dissolution of Poorly Soluble APIs with Inorganic Solid Dispersions

Gluing Pills Technology for the Production of Multi-Layer Tablets

Characterization of Polymeric Excipients

Predicting Multiparticulate Dissolution in Real Time for Modified- and Extended- Release Formulations

Wet Granulation Resolves Tablet Reformulation Challenges

Pharmaceutical Technology, 2017 Solid Dosage Supplement (PDF)

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!

Related Content

Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery

July 22nd 2025

Article

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery

May 30th 2025

Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent

July 18th 2025

Article

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific

March 28th 2025

Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.